Peringatan Keamanan

Reports of seizures (rare) have been reported

Reboxetine

DB00234

small molecule approved experimental

Deskripsi

Reboxetine is an antidepressant drug used in the treatment of clinical depression, panic disorder and ADD/ADHD. Its mesylate (i.e. methanesulfonate) salt is sold under tradenames including Edronax, Norebox, Prolift, Solvex, Davedax or Vestra. Reboxetine has two chiral centers, but it only exists as two enantiomers, (R,R)-(-)- and (S,S)-(+)-reboxetine.

Struktur Molekul 2D

Berat 313.397
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 12.5 hours
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Reboxetine is rapidly and extensively absorbed following oral administration.

Metabolisme

Reboxetine is metabolized by dealkylation, hydroxylation and oxidation followed by glucuronide or sulphate conjugation. It is metabolized by the cytochrome P450 CYP isoenzyme 3A4.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

896 Data
Buprenorphine Reboxetine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Reboxetine.
Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Reboxetine.
Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Reboxetine.
Hydrocodone Reboxetine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Reboxetine.
Magnesium sulfate The therapeutic efficacy of Reboxetine can be increased when used in combination with Magnesium sulfate.
Methotrimeprazine Reboxetine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Metyrosine Reboxetine may increase the sedative activities of Metyrosine.
Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Reboxetine.
Mirtazapine Reboxetine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Reboxetine.
Orphenadrine Reboxetine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Paraldehyde Reboxetine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Reboxetine.
Pramipexole Reboxetine may increase the sedative activities of Pramipexole.
Ropinirole Reboxetine may increase the sedative activities of Ropinirole.
Rotigotine Reboxetine may increase the sedative activities of Rotigotine.
Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Reboxetine.
Sodium oxybate Reboxetine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Suvorexant Reboxetine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Reboxetine.
Thalidomide Reboxetine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Zolpidem Reboxetine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Reboxetine.
Atomoxetine The metabolism of Atomoxetine can be decreased when combined with Reboxetine.
Dicoumarol The risk or severity of adverse effects can be increased when Reboxetine is combined with Dicoumarol.
Phenindione The risk or severity of adverse effects can be increased when Reboxetine is combined with Phenindione.
Coumarin The risk or severity of adverse effects can be increased when Reboxetine is combined with Coumarin.
Tioclomarol The risk or severity of adverse effects can be increased when Reboxetine is combined with Tioclomarol.
Warfarin The risk or severity of adverse effects can be increased when Reboxetine is combined with Warfarin.
Phenprocoumon The risk or severity of adverse effects can be increased when Reboxetine is combined with Phenprocoumon.
Acenocoumarol The risk or severity of adverse effects can be increased when Reboxetine is combined with Acenocoumarol.
4-hydroxycoumarin The risk or severity of adverse effects can be increased when Reboxetine is combined with 4-hydroxycoumarin.
(R)-warfarin The risk or severity of adverse effects can be increased when Reboxetine is combined with (R)-warfarin.
Ethyl biscoumacetate The risk or severity of adverse effects can be increased when Reboxetine is combined with Ethyl biscoumacetate.
Fluindione The risk or severity of adverse effects can be increased when Reboxetine is combined with Fluindione.
Clorindione The risk or severity of adverse effects can be increased when Reboxetine is combined with Clorindione.
Diphenadione The risk or severity of adverse effects can be increased when Reboxetine is combined with Diphenadione.
(S)-Warfarin The risk or severity of adverse effects can be increased when Reboxetine is combined with (S)-Warfarin.
Ethanol Reboxetine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Azelastine Reboxetine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Reboxetine.
Zimelidine The risk or severity of adverse effects can be increased when Reboxetine is combined with Zimelidine.
Dapoxetine The risk or severity of adverse effects can be increased when Reboxetine is combined with Dapoxetine.
Seproxetine The risk or severity of adverse effects can be increased when Reboxetine is combined with Seproxetine.
Fluvoxamine The risk or severity of adverse effects can be increased when Reboxetine is combined with Fluvoxamine.
Citalopram The risk or severity of adverse effects can be increased when Reboxetine is combined with Citalopram.
Duloxetine The risk or severity of adverse effects can be increased when Reboxetine is combined with Duloxetine.
Trazodone The risk or severity of adverse effects can be increased when Reboxetine is combined with Trazodone.
Paroxetine The risk or severity of adverse effects can be increased when Reboxetine is combined with Paroxetine.
Sertraline The risk or severity of adverse effects can be increased when Reboxetine is combined with Sertraline.
Sibutramine The risk or severity of adverse effects can be increased when Reboxetine is combined with Sibutramine.
Escitalopram The risk or severity of adverse effects can be increased when Reboxetine is combined with Escitalopram.
Milnacipran The risk or severity of adverse effects can be increased when Reboxetine is combined with Milnacipran.
Desvenlafaxine The risk or severity of adverse effects can be increased when Reboxetine is combined with Desvenlafaxine.
Levomilnacipran The risk or severity of adverse effects can be increased when Reboxetine is combined with Levomilnacipran.
Indalpine The risk or severity of adverse effects can be increased when Reboxetine is combined with Indalpine.
Ritanserin The risk or severity of adverse effects can be increased when Reboxetine is combined with Ritanserin.
Alaproclate The risk or severity of adverse effects can be increased when Reboxetine is combined with Alaproclate.
Iobenguane Reboxetine can cause a decrease in the absorption of Iobenguane resulting in a reduced serum concentration and potentially a decrease in efficacy.
Benzatropine The metabolism of Benzatropine can be decreased when combined with Reboxetine.
Tolterodine The metabolism of Tolterodine can be decreased when combined with Reboxetine.
Tiotropium The metabolism of Tiotropium can be decreased when combined with Reboxetine.
Solifenacin The metabolism of Solifenacin can be decreased when combined with Reboxetine.
Darifenacin The metabolism of Darifenacin can be decreased when combined with Reboxetine.
Nicardipine The metabolism of Reboxetine can be decreased when combined with Nicardipine.
Doxepin The risk or severity of CNS depression can be increased when Reboxetine is combined with Doxepin.
Fesoterodine The metabolism of Fesoterodine can be decreased when combined with Reboxetine.
Umeclidinium The metabolism of Umeclidinium can be decreased when combined with Reboxetine.
Revefenacin The metabolism of Revefenacin can be decreased when combined with Reboxetine.
Zopiclone The risk or severity of adverse effects can be increased when Reboxetine is combined with Zopiclone.
Botulinum toxin type B The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with Reboxetine.
Botulinum toxin type A The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Reboxetine.
Baclofen Baclofen may increase the central nervous system depressant (CNS depressant) activities of Reboxetine.
Ethchlorvynol The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Reboxetine.
Succinylcholine The risk or severity of CNS depression can be increased when Succinylcholine is combined with Reboxetine.
Enflurane The risk or severity of CNS depression can be increased when Enflurane is combined with Reboxetine.
Butabarbital The risk or severity of CNS depression can be increased when Reboxetine is combined with Butabarbital.
Butalbital The risk or severity of CNS depression can be increased when Reboxetine is combined with Butalbital.
Clemastine The risk or severity of CNS depression can be increased when Reboxetine is combined with Clemastine.
Etomidate The risk or severity of CNS depression can be increased when Reboxetine is combined with Etomidate.
Talbutal The risk or severity of CNS depression can be increased when Reboxetine is combined with Talbutal.
Zolmitriptan The risk or severity of CNS depression can be increased when Reboxetine is combined with Zolmitriptan.
Codeine The risk or severity of CNS depression can be increased when Reboxetine is combined with Codeine.
Tolcapone The risk or severity of CNS depression can be increased when Reboxetine is combined with Tolcapone.
Hydromorphone The risk or severity of CNS depression can be increased when Reboxetine is combined with Hydromorphone.
Trimethadione The risk or severity of CNS depression can be increased when Reboxetine is combined with Trimethadione.
Chlorzoxazone The risk or severity of CNS depression can be increased when Reboxetine is combined with Chlorzoxazone.
Thiethylperazine The risk or severity of CNS depression can be increased when Reboxetine is combined with Thiethylperazine.
Palonosetron The risk or severity of CNS depression can be increased when Reboxetine is combined with Palonosetron.
Dexbrompheniramine The risk or severity of CNS depression can be increased when Reboxetine is combined with Dexbrompheniramine.
Metocurine iodide The risk or severity of CNS depression can be increased when Reboxetine is combined with Metocurine iodide.
Secobarbital The risk or severity of CNS depression can be increased when Reboxetine is combined with Secobarbital.
Methocarbamol The risk or severity of CNS depression can be increased when Reboxetine is combined with Methocarbamol.
Triprolidine The risk or severity of CNS depression can be increased when Reboxetine is combined with Triprolidine.
Cyproheptadine The risk or severity of CNS depression can be increased when Reboxetine is combined with Cyproheptadine.
Metharbital The risk or severity of CNS depression can be increased when Reboxetine is combined with Metharbital.
Methohexital The risk or severity of CNS depression can be increased when Reboxetine is combined with Methohexital.
Gallamine triethiodide The risk or severity of CNS depression can be increased when Reboxetine is combined with Gallamine triethiodide.

Target Protein

Sodium-dependent noradrenaline transporter SLC6A2

Referensi & Sumber

Artikel (PubMed)
  • PMID: 11192474
    Fleishaker JC: Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression. Clin Pharmacokinet. 2000 Dec;39(6):413-27.
  • PMID: 7579027
    Edwards DM, Pellizzoni C, Breuel HP, Berardi A, Castelli MG, Frigerio E, Poggesi I, Rocchetti M, Dubini A, Strolin Benedetti M: Pharmacokinetics of reboxetine in healthy volunteers. Single oral doses, linearity and plasma protein binding. Biopharm Drug Dispos. 1995 Aug;16(6):443-60.
  • PMID: 10534319
    Wienkers LC, Allievi C, Hauer MJ, Wynalda MA: Cytochrome P-450-mediated metabolism of the individual enantiomers of the antidepressant agent reboxetine in human liver microsomes. Drug Metab Dispos. 1999 Nov;27(11):1334-40.
  • PMID: 11249515
    Kasper S, el Giamal N, Hilger E: Reboxetine: the first selective noradrenaline re-uptake inhibitor. Expert Opin Pharmacother. 2000 May;1(4):771-82.

Contoh Produk & Brand

Produk: 0 • International brands: 6
International Brands
  • Davedax
  • Edronax
  • Norebox
  • Prolift
  • Solvex
  • Vestra

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul